AKT1 and breast carcinoma: To determine if FAK inhibition alters Akt or mTOR activation in breast carcinoma cells, lysates of MCF7, BT474, MDA-MB-468, MDA-MB-231, and 4T1L treated with DMSO (control) or 0.1 μM PF-271 FAK inhibitor for 3 days were evaluated by immunoblotting (Figure 5C).